| Literature DB >> 20473695 |
Didier L Schrijvers1, Ellen R A De Bruijn, Marianne Destoop, Wouter Hulstijn, Bernard G C Sabbe.
Abstract
Perfectionism and anxiety features are involved in the clinical presentation and neurobiology of major depressive disorder (MDD). In MDD, cognitive control mechanisms such as action monitoring can adequately be investigated applying electrophysiological registrations of the error-related negativity (ERN) and error positivity (Pe). It is also known that traits of perfectionism and anxiety influence ERN amplitudes in healthy subjects. The current study explores the impact of perfectionism and anxiety traits on action monitoring in MDD. A total of 39 MDD patients performed a flankers task during an event-related potential (ERP) session and completed the multidimensional perfectionism scale (MPS) with its concern over mistakes (CM) and doubt about actions (DA) subscales and the trait form of the State Trait Anxiety Inventory. Multiple regression analyses with stepwise backward elimination revealed MPS-DA to be a significant predictor (R (2):0.22) for the ERN outcomes, and overall MPS (R (2):0.13) and MPS-CM scores (R (2):0.18) to have significant predictive value for the Pe amplitudes. Anxiety traits did not have a predictive capacity for the ERPs. MPS-DA clearly affected the ERN, and overall MPS and MPS-CM influenced the Pe, whereas no predictive capacity was found for anxiety traits. The manifest impact of perfectionism on patients' error-related ERPs may contribute to our understanding of the action-monitoring process and the functional significance of the Pe in MDD. The divergent findings for perfectionism and anxiety features also indicate that the wide range of various affective personality styles might exert a different effect on action monitoring in MDD, awaiting further investigation.Entities:
Mesh:
Year: 2010 PMID: 20473695 PMCID: PMC2895873 DOI: 10.1007/s00702-010-0419-2
Source DB: PubMed Journal: J Neural Transm (Vienna) ISSN: 0300-9564 Impact factor: 3.575
Medication schemes for each patient
| Subject number | Medication (dosage in mg/day) |
|---|---|
| 1 | Venlafaxine (225), Prazepam (10) |
| 2 | Venlafaxine (150), Lormetazepam (2) |
| 3 | Venlafaxine (150), Trazodone (100) |
| 4 | Venlafaxine (150), Mirtazapine (30), Prothipendyl (80) |
| 5 | Paroxetine (20), Mirtazapine (15), Quetiapine (500) |
| 6 | Escitalopram (10), Clonazepam (0.5) |
| 7 | Venlafaxine (150), Trazodone (150), Clorazepate (30) |
| 8 | Venlafaxine (225), Mirtazapine (30), Quetiapine (400) |
| 9 | Clomipramine (150), Mirtazapine (30), Lormetazepam (2) |
| 10 | Dosulepine (150) |
| 11 | Escitalopram (10), Mirtazapine (30), Amisulpride (800) |
| 12 | Paroxetine (10), Quetiapine (300), Lorazepam (3) |
| 13 | Escitalopram (10), Trazodone (100), Risperidone (2), Alprazolam (2) |
| 14 | Mirtazapine (30) |
| 15 | Fluoxetine (20), Trazodone (200), Amisulpride (50) |
| 16 | Mirtazapine, (30), Alprazolam (0.5) |
| 17 | Venlafaxine (150), Amisulpride (50) |
| 18 | Venlafaxine (225), Trazodone (100) |
| 19 | / |
| 20 | Venlafaxine (75) |
| 21 | Fluvoxamine (100), Aripiprazole (10) |
| 22 | Escitalopram (10), Trazodone (100) |
| 23 | Paroxetine (30), Quetiapine (200) |
| 24 | Escitalopram (10), Trazodone (50) |
| 25 | Venlafaxine (225), Mirtazapine (30), Risperidone (2) |
| 26 | Escitalopram (10) |
| 27 | Escitalopram (10), Trazodone (50), Risperidone (2) |
| 28 | Escitalopram (10), Quetiapine (100) |
| 29 | Venlafaxine (150) |
| 30 | Paroxetine (40), Mirtazapine (30), Clonazepam (0.5) |
| 31 | Paroxetine (20), Mirtazapine (30), Tetrazepam (25) |
| 32 | Escitalopram (20), Trazodone (100) |
| 33 | Paroxetine (40) |
| 34 | Escitalopram (20), Trazodone (100) |
| 35 | Escitalopram (20), Trazodone (100), Clorazepate (10) |
| 36 | Escitalopram (20) |
| 37 | Fluvoxamine (400), Mirtazapine (30) |
| 38 | Paroxetine (40), Trazodone (100) |
| 39 | Escitalopram (20) |
Mean values for medication (standard deviation) were as follows: antidepressants (reference substance: imipramine): 223 mg (103); neuroleptics (reference substance: chlorpromazine): 261.5 mg (197); benzodiazepines (reference substance: diazepam): 8.7 mg (5.4)
Bivariate Pearson correlations between the total scores on the Hamilton depression rating scale (HDRS), the overall multidimensional perfectionism scores as well as its subscales concern over mistakes (MPS-CM), doubt about actions (MPS-DA), personal standards (MPS-PS), the trait scores (STAI-T) of the state-trait anxiety inventory and the ERN amplitudes at Fz and Pe amplitudes at Pz for all patients (n = 39)
| HDRS | Overall MPS | MPS-PS | MPS-CM | MPS-DA | STAI-T | ERN (Fz) | Pe (Pz) | |
|---|---|---|---|---|---|---|---|---|
| HDRS | 1 | 0.075 | −0.01 | 0.16 | −0.02 | 0.23# | 0.06 | −0.03 |
| Overall MPS | × | 1 | 0.86*** | 0.90*** | 0.54*** | 0.28* | −0.19 | 0.36* |
| MPS-PS | × | × | 1 | 0.75*** | 0.36# | 0.31* | −0.089 | 0.212 |
| MPS-CM | × | × | × | 1 | 0.48*** | 0.31* | −0.09 | 0.43** |
| MPS-DA | × | × | × | × | 1 | 0.06 | −0.47** | 0.18 |
| STAI-T | × | × | × | × | × | 1 | −0.14 | 0.25# |
| ERN (Fz) | × | × | × | × | × | × | 1 | −0.003 |
| Pe (Pz) | × | × | × | × | × | × | × | 1 |
# p < 0.1; * p < 0.05; ** p < 0.01; *** p < 0.001
Backward stepwise multivariate regression model for the error-related negativity (at Fz) and the error positivity (at Pz)
|
| B value |
|
| 95% Confidence interval for B | ||
|---|---|---|---|---|---|---|
| ERN (Fz) | ||||||
| Model 1 | Overall MPS | 0.038 | −0.038 | −0.195 | 0.23 | −0.102; 0.026 |
| Model 2 | MPS-DA | 0.222 | −0.562 | −0.471 | 0.002 | −0.913; −0.212 |
| Pe (Pz) | ||||||
| Model 1 | Overall MPS | 0.132 | 0.094 | 0.363 | 0.023 | 0.014; 0.174 |
| Model 2 | MPS-CM | 0.185 | 0.293 | 0.430 | 0.006 | 0.088; 0.499 |
Outcome measures (dependent variables) included determinants for each model (independent variables), R², B value (unstandardized coefficient) and β value (standardized coefficient) for each determinant and p value (significance); the last column represents the corresponding 95% confidence interval for each predictor. The excluded determinants for each model are not described in this table
Overall MPS, overall score of the multidimensional perfectionism scale; MPS-DA, doubts about action subdimension of the MPS; MPS-CM, concern over mistakes subdimension of the MPS
Fig. 1Grand average response-locked waveforms for the correct and incorrect responses for the patients with high and those with low scores on the multidimensional perfectionism subscales concern over mistakes and doubt about actions. The output of electrodes Fz, Cz and Pz are depicted. Responses are given at t = 0 ms